<DOC>
	<DOCNO>NCT02797015</DOCNO>
	<brief_summary>The purpose study learn pharmacokinetics pharmacodynamics RPC1063 RMS .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Study RPC1063 RMS</brief_title>
	<detailed_description>The purpose study characterize full pharmacokinetic pharmacodynamics profile RPC1063 patient relapse multiple sclerosis ( RMS ) follow multiple-dose administration two different dose regimen evaluate Phase 3 RMS study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Key MS , diagnose revised 2010 McDonald criterion Exhibits relapse clinical course consistent RMS history brain MRI lesion consistent MS Expanded disability status scale ( EDSS ) score 0 6.0 Key Primary progressive MS Clinically relevant cardiovascular condition relevant disease could impact implementation interpretation trial , put patient risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>RMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
</DOC>